APC2 and prostate cancer: miR-3648 facilitates prostate cancer cell proliferation by inhibiting APC2, which leads to the activation of the Wnt/β-catenin pathway by increasing cyclin D1 and cyclin E1 expression and decreasing p21 expression [13].